USD
+$0.00
(+0.00%
)At Close (As of Sep 17, 2025)
$525.32M
Market Cap
-
P/E Ratio
-0.42
EPS
$25.50
52 Week High
$6.71
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $168M |
Total Revenue | $168M |
Cost Of Revenue | $3.3M |
Costof Goods And Services Sold | $3.3M |
Operating Income | $58M |
Selling General And Administrative | $26M |
Research And Development | $83M |
Operating Expenses | $110M |
Investment Income Net | - |
Net Interest Income | $4.7M |
Interest Income | $4.7M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.3M |
Income Before Tax | $53M |
Income Tax Expense | $1.2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $52M |
Comprehensive Income Net Of Tax | - |
Ebit | $58M |
Ebitda | $61M |
Net Income | $52M |
Field | Value (USD) |
---|---|
Total Assets | $241M |
Total Current Assets | $202M |
Cash And Cash Equivalents At Carrying Value | $197M |
Cash And Short Term Investments | $197M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $39M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $4.9M |
Other Non Current Assets | - |
Total Liabilities | $552M |
Total Current Liabilities | $21M |
Current Accounts Payable | $1.9M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $9.3M |
Total Non Current Liabilities | $531M |
Capital Lease Obligations | $27M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $27M |
Other Current Liabilities | $9.5M |
Other Non Current Liabilities | $969K |
Total Shareholder Equity | -$311M |
Treasury Stock | - |
Retained Earnings | -$358M |
Common Stock | $2K |
Common Stock Shares Outstanding | $44M |
Field | Value (USD) |
---|---|
Operating Cashflow | $76M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3.3M |
Capital Expenditures | $1.1M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$1.1M |
Cashflow From Financing | $93M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $52M |
Field | Value (USD) |
---|---|
Gross Profit | $168M |
Total Revenue | $168M |
Cost Of Revenue | $3.3M |
Costof Goods And Services Sold | $3.3M |
Operating Income | $58M |
Selling General And Administrative | $26M |
Research And Development | $83M |
Operating Expenses | $110M |
Investment Income Net | - |
Net Interest Income | $4.7M |
Interest Income | $4.7M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.3M |
Income Before Tax | $53M |
Income Tax Expense | $1.2M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $52M |
Comprehensive Income Net Of Tax | - |
Ebit | $58M |
Ebitda | $61M |
Net Income | $52M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity. With its headquarters in South San Francisco, California, the company leverages cutting-edge genetic insights to drive its innovative therapeutic pipeline. As it advances its clinical programs, Maze aims to address significant unmet medical needs, positioning itself as a leader in the precision medicine landscape.